Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16780714 | 1.00 | PDE4B (0.48) | PDE4BRORCTACR1USP30GPR119 | |
| SCHEMBL16780718 | 1.00 | PDE4B (0.48) | PDE4BRORCTACR1USP30GPR119 | |
| SCHEMBL16780715 | 1.00 | PDE4B (0.48) | PDE4BRORCTACR1USP30GPR119 | |
| SCHEMBL6310349 | 0.86 | DPP4 (0.53) | PDE4BRORCTACR1USP30STS | |
| SCHEMBL13077736 | 0.85 | PDE4B (0.48) | PDE4BRORCTACR1USP30GPR119 | |
| SCHEMBL16780215 | 0.85 | RORC (0.51) | PDE4BRORCTACR1USP30GPR119 | |
| SCHEMBL13858400 | 0.85 | RORC (0.51) | PDE4BRORCTACR1USP30GPR119 | |
| SCHEMBL3744409 | 0.85 | PDE4B (0.48) | PDE4BRORCTACR1USP30GPR119 | |
| SCHEMBL16780217 | 0.85 | RORC (0.51) | PDE4BRORCTACR1USP30GPR119 | |
| SCHEMBL31449726 | 0.85 | PDE4B (0.45) | PDE4BRORCTACR1STSNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | PDE4B 498/4885RORC 2129/4885TACR1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.